Ethanolamine formulation for treating epithelial ovarian carcinoma

Abstract

Monoethanolamine (Etn) displays strong in vitro and in vivo efficacy in prostate cancer cell lines and xenograft models, respectively, as well as in cell lines from diverse cancer types. Etn is a pro-drug, which upon entry into tumor cells, is converted into cytotoxic phosphoethanolamine (PhosE). Etn treatment potently down-regulates HIF-1α and drives a catastrophic uncoupling of multiple pathways to induce metabolic crisis and cell death, selectively in tumor cells, while sparing normal cells. Importantly, the ovarian cancer cell line OVCAR3 was more sensitive to Etn than all the prostate, breast, colon, and pancreatic cancer cell lines tested. An Etn-based formulation with favorable pharmacokinetics/pharmacodynamics (PK/PD) can therefore in some embodiments be used as single therapeutic for EOC or OCCC.

Dependencies are inferred from the claim text.